Indeed, IL-6 has been demonstrated to activate STAT3/NF-κB signaling, which consequently sustains EMT in breast cancer, and to modulate the tumor microenvironment, linking inflammation to cancer progression and drug resistance [13, 17–21]. Here, NFKB1 is linked to breast carcinoma.